Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diacetylmorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 13/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.64 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diacetylmorphine SCHEMBL28409302 | 0.98 | OPRD1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL6471789 | 0.97 | OPRD1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL11498298 | 0.96 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL35150 | 0.95 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL13998950 | 0.95 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL10381363 | 0.95 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL16922136 | 0.95 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL14463869 | 0.95 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL16922130 | 0.95 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL16183153 | 0.95 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | OPRM1 4699/4885OPRD1 4049/4885OPRK1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.